Literature DB >> 1551913

Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent.

R A Hurta1, J A Wright.   

Abstract

Ribonucleotide reductase provides the four deoxyribonucleotides required for the synthesis of DNA. In this study, we examined the hypothesis that alterations in the regulation of ribonucleotide reductase activity may be necessary to provide the deoxyribonucleotides required for DNA repair, following exposure of mammalian cells to DNA damaging agents such as the antitumor agent chlorambucil. We observed a marked transient increase in ribonucleotide reductase activity within 2 h of exposing BALB/c 3T3 mouse cells to DNA damaging concentrations of chlorambucil. Northern blot analysis showed that elevations in activity were accompanied by transient increases in the mRNA levels of both genes (R1 and R2) that code for ribonucleotide reductase. Western blot analysis indicated that only the protein for the limiting component for enzyme activity, R2, was significantly elevated in chlorambucil treated cultures. The chlorambucil effects upon activity and regulation of ribonucleotide reductase occurred without any detectable changes in the rate of DNA synthesis, as would be expected if the elevation in enzyme activity is required for DNA repair. The chlorambucil-induced elevations in R1 and R2 message levels were blocked by treatment of cells with actinomycin D or the tumor promoter 12-O-tetradecanoylphorbol-13-acetate, indicating the importance of the reductase transcriptional process in responding to the action of chlorambucil and providing evidence for the involvement of a protein kinase C pathway in the regulation of mammalian ribonucleotide reductase. In addition to the chlorambucil-induced elevations in enzyme activity, message, and protein levels, the drug was also shown to be an inhibitor of ribonucleotide reductase activity in cell-free preparations. Separation of ribonucleotide components on an affinity column followed by selective exposure of the protein components to chlorambucil showed that both R1 and R2 proteins were targets for chlorambucil, in keeping with the known alkylating abilities of the drug. These observations provide the first direct demonstration of a link between the regulation of mammalian ribonucleotide reductase and the process of DNA repair and contribute to our understanding of the mode of action of a class of drugs represented by chlorambucil, in which chemotherapeutic activity has been attributed to DNA damaging effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551913

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Defining a novel ribonucleotide reductase r1 mRNA cis element that binds to an unique cytoplasmic trans-acting protein.

Authors:  F Y Chen; F M Amara; J A Wright
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

2.  Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Stefan Faderl; Kumudha Balakrishnan; Deborah A Thomas; Farhad Ravandi; Gautam Borthakur; Jan Burger; Alessandra Ferrajoli; Jorge Cortes; Susan O'Brien; Tapan Kadia; Jennie Feliu; William Plunkett; Varsha Gandhi; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-17

Review 3.  Thioredoxin and glutaredoxin-mediated redox regulation of ribonucleotide reductase.

Authors:  Rajib Sengupta; Arne Holmgren
Journal:  World J Biol Chem       Date:  2014-02-26

4.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.

Authors:  H Fan; A Huang; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  A novel transforming growth factor-beta 1 responsive cytoplasmic trans-acting factor binds selectively to the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability.

Authors:  F M Amara; F Y Chen; J A Wright
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

6.  DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.

Authors:  Martha Rodriguez Sandoval; Kumudha Balakrishnan; Rajyalakshmi Luthra; Michael Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2013-07-29

7.  Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Authors:  Amal A El-Mabhouh; Mary L Ayres; Elizabeth J Shpall; Veerabhadran Baladandayuthapani; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

8.  Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.

Authors:  R A Jensen; D L Page; J T Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

9.  Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.

Authors:  M I Anazodo; M A Wainberg; A D Friesen; J A Wright
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Authors:  Stephen I Shibata; James H Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim A Margolin; Robert J Morgan; George Somlo; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.